<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185363</url>
  </required_header>
  <id_info>
    <org_study_id>MRX-503</org_study_id>
    <nct_id>NCT04185363</nct_id>
  </id_info>
  <brief_title>An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)</brief_title>
  <official_title>An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this open label extension study is to evaluate the long-term safety
      and tolerability of maralixibat.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at multiple sites in North America, Europe, Asia, and South
      America.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 8, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs) during the study</measure>
    <time_frame>From baseline through study completion, up to 104 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from maralixibat baseline over the course of the study in the weekly average morning ItchRO(Obs)™ (Itch Reported Outcome) severity score</measure>
    <time_frame>From baseline through study completion,up to 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from maralixibat baseline over the course of the study in the weekly average morning ItchRO(Obs)™ (Itch Reported Outcome) frequency score</measure>
    <time_frame>From baseline through study completion,up to 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline over time in serum bile acid (sBA) levels</measure>
    <time_frame>From baseline through study completion,up to 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline over time in height and weight z-scores</measure>
    <time_frame>From baseline through study completion,up to 104 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Progressive Familial Intrahepatic Cholestasis (PFIC)</condition>
  <arm_group>
    <arm_group_label>Maralixibat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive Maralixibat oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maralixibat</intervention_name>
    <description>All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) twice daily for up to 104 weeks</description>
    <arm_group_label>Maralixibat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Provide informed consent and assent (as applicable) per Institutional Review
             Board/Ethics Committee (IRB/EC)

          2. Completion of study MRX-502

        Exclusion Criteria:

          1. Any female who is pregnant or lactating or who is planning to become pregnant

          2. Administration of prohibited medication between the MRX-502 EOT visit and the MRX 503
             Baseline Visit (Day 0)

          3. History of non-compliance in study MRX-502, non-adherence to medical regimens,
             unreliability, mental instability or incompetence that could compromise the validity
             of informed consent or lead to non-adherence with the study protocol based on
             Investigator judgment

          4. Experienced an adverse event (AE) or serious adverse event (SAE) related to
             maralixibat during the MRX-502 study that led to permanent discontinuation of the
             subject from maralixibat

          5. Any other conditions or laboratory abnormalities that, in the opinion of the
             Investigator or Sponsor Medical Monitor, may compromise the safety of the subject, or
             interfere with the subject participating in or completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://ghr.nlm.nih.gov/condition/progressive-familial-intrahepatic-cholestasis</url>
    <description>Genetics Home Reference - PFIC</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>US FDA Resources</description>
  </link>
  <link>
    <url>https://mirumpharma.com/</url>
    <description>Mirum Pharmaceuticals homepage</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholestasis</keyword>
  <keyword>Maralixibat</keyword>
  <keyword>Mutation</keyword>
  <keyword>PFIC</keyword>
  <keyword>PFIC2</keyword>
  <keyword>Bile Duct Diseases</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Biliary Tract Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

